Price
$30.08
Increased by +1.76%
Dollar volume (20D)
44.82 M
ADR%
3.46
Earnings report date
Nov 4, 2025
Shares float
92.80 M
Shares short
8.41 M [9.06%]
Shares outstanding
96.37 M
Market cap
2.85 B
Beta
0.24
Price/earnings
N/A
20D range
26.52 30.52
50D range
25.81 42.37
200D range
25.81 53.04

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.

It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.

Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Reported date EPSChange YoY EstimateSurprise
Aug 5, 25 -1.17
Increased by +23.03%
-1.30
Increased by +10.00%
Apr 30, 25 -1.57
Increased by +22.66%
-1.75
Increased by +10.29%
Feb 13, 25 -1.39
Increased by +8.55%
-1.27
Decreased by -9.45%
Nov 5, 24 -1.40
Increased by +37.22%
-1.45
Increased by +3.45%
Aug 1, 24 -1.52
Increased by +32.44%
-1.69
Increased by +10.06%
May 2, 24 -2.03
Increased by +12.88%
-1.73
Decreased by -17.34%
Feb 15, 24 -1.52
Increased by +29.63%
-1.62
Increased by +6.17%
Nov 2, 23 -2.23
Increased by +36.29%
-2.08
Decreased by -7.21%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 166.50 M
Increased by +13.24%
-114.95 M
Increased by +12.65%
Decreased by -69.04%
Increased by +22.86%
Mar 31, 25 139.29 M
Increased by +27.99%
-151.08 M
Increased by +11.49%
Decreased by -108.46%
Increased by +30.84%
Dec 31, 24 164.88 M
Increased by +29.42%
-133.38 M
Decreased by -8.28%
Decreased by -80.90%
Increased by +16.34%
Sep 30, 24 139.49 M
Increased by +42.27%
-133.52 M
Increased by +16.37%
Decreased by -95.71%
Increased by +41.21%
Jun 30, 24 147.03 M
Increased by +35.75%
-131.60 M
Increased by +17.66%
Decreased by -89.51%
Increased by +39.34%
Mar 31, 24 108.83 M
Increased by +8.30%
-170.68 M
Decreased by -4.09%
Decreased by -156.83%
Increased by +3.88%
Dec 31, 23 127.39 M
Increased by +23.27%
-123.19 M
Increased by +18.86%
Decreased by -96.70%
Increased by +34.18%
Sep 30, 23 98.05 M
Increased by +8.10%
-159.65 M
Increased by +34.87%
Decreased by -162.82%
Increased by +39.75%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY